Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

ProMIS Neurosciences Q3 2026 Results: Net Loss of $8.2M, Loss Narrows

ProMIS Neurosciences reported a significant increase in cash to $44.1 million as of September 30, 2026, compared to $6.1 million at the end of 2025, primarily driven by financing activities that increased additional paid-in capital. The company's accumulated deficit grew to $158.5 million, reflecting ongoing research and development costs, while total shareholders' equity improved to a positive $41.8 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-8.2-11.6
EPS (diluted, $ a share)$-0.89$-5.93

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: PMN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

ProMIS Neurosciences Inc.: key numbers

Share price
$3.31Close, Nov 16
Market cap
$29.8M
Shares outstanding
9MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from ProMIS Neurosciences Inc.

All →
4:18 PM ET 8-K
Financial Results

ProMIS Neurosciences Financial Results

ProMIS Neurosciences reported Q3 2026 financial results, ending the period with $44.1 million in cash which is expected to fund operations through 2027. The company reaffirmed that topline data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer’s disease remains on track for the first quarter of 2027.

Term
Q3 2026

“The third quarter of 2026 has been productive for ProMIS, following encouraging interim data from our Phase 1b PRECISE-AD trial in Alzheimer’s disease (AD). Based on data generated to date, we continue to believe PMN310 offers a differentiated approach by selectively targeting the most toxic and destructive form of amyloid-beta, the oligomers.”

Neil Warma, President and Chief Executive Officer

“With PRECISE-AD closing out its final stage of patient visits, we look forward to reporting topline data in the first quarter of 2027, which will include safety, biomarker and clinical efficacy measures.”

Neil Warma, President and Chief Executive Officer
8:01 AM ET 8-K
Investor Presentation

ProMIS Neurosciences Investor Presentation

ProMIS Neurosciences Inc. has posted an updated corporate presentation to its website and filed it as an exhibit to its 8-K. The presentation provides a strategic overview of the company's development pipeline, including its PMN310 candidate for Alzheimer's disease and the PRECISE-AD Phase 1b clinical trial. The filing serves as a Regulation FD disclosure to provide investors with current information on the company's operations and clinical milestones.

8:15 AM ET Form 4
Insider Buying

ProMIS Neurosciences Insider Eugene Williams Buys $90.9K of Stock

Eugene Williams bought 26,500 shares of ProMIS Neurosciences Inc. at $3.43 a share, worth $90.9K in total on Nov 4, 2026. Shares held after the trade: 40,213 (+193.2%).

Value
$90.9K
Shares
26,500
Price
$3.43
Holding change
+193.2%
Trade date
Nov 4, 2026
8:27 AM ET Form 4
Insider Buying

ProMIS Neurosciences CSO Neil Cashman Buys $38.6K of Stock

Neil Cashman, CSO, bought 10,000 shares of ProMIS Neurosciences Inc. at $3.86 a share, worth $38.6K in total on Nov 2, 2026. Shares held after the trade: 14,532 (+220.7%).

Value
$38.6K
Shares
10,000
Price
$3.86
Role
CSO
Holding change
+220.7%
Trade date
Nov 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.